In another clinical trial aimed at correcting alpha antitrypsin (AAT) deficiency, capsid-specific gamma interferon (IFNg)-secreting cells were detected in rAAV1-injected patients using an ELISpot assay despite persisting transgene expression [13,14,15,16]. The gene discussed is IFNG; the disease is alpha 1-antitrypsin deficiency.